Integra Lifesciences Holdings (IART) Total Non-Current Liabilities (2009 - 2026)

Integra Lifesciences Holdings' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $2.3 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 1.2% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $2.3 billion (down 1.2% YoY), while the FY2025 annual figure was $2.4 billion, changed 0.36% from the prior year.
• Total Non-Current Liabilities came in at $2.3 billion for Q1 2026 at Integra Lifesciences Holdings, down from $2.4 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $2.4 billion in Q2 2024 to a low of $1.9 billion in Q1 2023.
• A 5-year average of $2.2 billion and a median of $2.3 billion in 2026 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities retreated 4.66% in 2022 and rose 22.89% in 2024, its largest moves.
• Integra Lifesciences Holdings' Total Non-Current Liabilities stood at $2.1 billion in 2022, then decreased by 3.21% to $2.0 billion in 2023, then rose by 17.64% to $2.3 billion in 2024, then grew by 0.36% to $2.4 billion in 2025, then slipped by 0.62% to $2.3 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $2.3 billion, $2.4 billion, and $2.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison